A summary of second-line randomized studies of aromatase inhibitors
- 1 December 2001
- journal article
- research article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 79 (1-5) , 109-114
- https://doi.org/10.1016/s0960-0760(01)00150-9
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Letrozole: Updated Duration of ResponseJournal of Clinical Oncology, 1999
- Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinomaCancer, 1998
- Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.Journal of Clinical Oncology, 1998
- The preclinical pharmacology of “Arimidex” (Anastrozole; ZD1033) — a potent, selective aromatase inhibitorThe Journal of Steroid Biochemistry and Molecular Biology, 1996
- Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multiinstitutional trialsCancer, 1996
- Tamoxifen for Breast Cancer PreventionExperimental Biology and Medicine, 1995
- Hormonal treatment for metastatic breast cancer. An eastern cooperative oncology group phase III trial comparing aminoglutethimide to tamoxifenCancer, 1994
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992
- Tamoxifen in advanced breast cancerCancer Treatment Reviews, 1978
- Medical Adrenalectomy with AminoglutethimideAnnals of Surgery, 1978